Published in Eur J Clin Pharmacol on October 15, 2016
European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg (1999) 17.03
Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation (2007) 5.31
Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb (2003) 4.44
Blood transfusion is associated with increased resource utilisation, morbidity and mortality in cardiac surgery. Ann Card Anaesth (2008) 3.29
The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. Ann Thorac Surg (2008) 2.29
Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost (2006) 2.01
A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg (2006) 2.00
The ongoing variability in blood transfusion practices in cardiac surgery. Transfusion (2008) 1.90
Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg (2009) 1.69
Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med (2004) 1.60
Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa. Blood (2011) 1.50
Cardiac surgery in Germany during 2008. A report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg (2009) 1.45
Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg (2006) 0.99
The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb (2004) 0.95
Anticoagulant therapy during cardiopulmonary bypass. J Thromb Thrombolysis (2008) 0.95
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost (2009) 0.93
Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res (1997) 0.87
Blood transfusion is associated with increased resource utilisation, morbidity, and mortality in cardiac surgery. Ann Card Anaesth (2008) 0.79
Focus on thrombin: alternative anticoagulants. Semin Cardiothorac Vasc Anesth (2007) 0.79
First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action. Eur J Clin Pharmacol (2016) 0.78
First in man study of EP217609, a new long-acting, neutralisable parenteral antithrombotic with a dual mechanism of action. Eur J Clin Pharmacol (2016) 0.78